NASDAQ:EYESSecond Sight Medical Products Stock Price, Forecast & News

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EYES shares have decreased by 71.1% and is now trading at $1.02. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products.

Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings results on Thursday, March, 19th. The medical device company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.01. The medical device company earned $0.50 million during the quarter, compared to analysts' expectations of $0.83 million. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 183.76%. View Second Sight Medical Products' earnings history.

2 Wall Street analysts have issued 12-month target prices for Second Sight Medical Products' stock. Their forecasts range from $2.00 to $2.50. On average, they expect Second Sight Medical Products' share price to reach $2.25 in the next year. This suggests a possible upside of 120.6% from the stock's current price. View analysts' price targets for Second Sight Medical Products.

News headlines about EYES stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutSecond Sight Medical Products.

Second Sight Medical Products saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 774,600 shares, an increase of 9.0% from the April 30th total of 710,700 shares. Based on an average trading volume of 293,600 shares, the days-to-cover ratio is presently 2.6 days. Currently, 10.2% of the shares of the stock are sold short. View Second Sight Medical Products' Current Options Chain.

Some companies that are related to Second Sight Medical Products include Fc Global Realty (FCRE), electroCore (ECOR), IRIDEX (IRIX), Reshape Lifesciences (RSLS), Helius Medical Technologies (HSDT), Precision Optics (PEYE), CHF Solutions (CHFS), ENDRA Life Sciences (NDRA), Viveve Medical (VIVE), Vaso (VASO), Digirad (DRAD), Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD), Guided Therapeutics (GTHP) and Nexeon Medsystems (NXNN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Canopy Growth (CGC), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP), TransEnterix (TRXC) and Plug Power (PLUG).

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (3.59%) and BlackRock Inc. (0.25%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View institutional ownership trends for Second Sight Medical Products.

EYES stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, and BlackRock Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph, and Jonathan Will Mcguire. View insider buying and selling activity for Second Sight Medical Products.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $1.02.

Second Sight Medical Products has a market capitalization of $15.97 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

The official website for Second Sight Medical Products is www.secondsight.com.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]